WO2025046421 - METHODS OF USING FACTOR B INHIBITORS
National phase entry:
Publication Number
WO/2025/046421
Publication Date
06.03.2025
International Application No.
PCT/IB2024/058205
International Filing Date
23.08.2024
Title **
[English]
METHODS OF USING FACTOR B INHIBITORS
[French]
PROCÉDÉS D'UTILISATION D'INHIBITEURS DU FACTEUR B
Applicants **
NOVARTIS AG
Inventors
JÖRG, Eder
HOLBRO, Thomas
KARAN, Rajesh Singh
KIESEIER, Bernd C.
WELLENSIEK, Anna Svenja Schubart
Priority Data
63/578,694
25.08.2023
US
63/668,430
08.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5641 | |
| EPO | Filing, Examination, Granting | 126590 | |
| Japan | Filing, Examination, Granting | 4931 | |
| South Korea | Filing, Examination, Granting | 9066 | |
| USA | Filing, Examination, Granting | 32940 |
Total:
179,168
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Described herein are methods of treating gMG (generalized Myasthenia gravis) with the Factor B inhibitor iptacopan or a pharmaceutically acceptable salt or hydrate thereof.[French]
L'invention concerne des procédés de traitement de la MGg (myasthénie grave généralisée) avec l'inhibiteur du facteur B iptacopan ou un sel ou un hydrate pharmaceutiquement acceptable de celui-ci.